Monoclonal and bispecific antibodies as novel therapeutics

Archivum Immunologiae Et Therapiae Experimentalis
Evan P BooyMarek Los

Abstract

Gene amplification, over-expression, and mutation of growth factors, or the receptors themselves, causes increased signaling through receptor kinases, which has been implicated in many human cancers and is associated with poor prognosis. Tumor growth has been shown to be decreased by interrupting this process of extensive growth factor-mediated signaling by directly targeting either the surface receptor or the ligand and thereby preventing cell survival and promoting apoptosis. Monoclonal antibodies have long been eyed as a potential new class of therapeutics targeting cancer and other diseases. Antibody-based therapy initially entered clinical practice when trastuzumab/Herceptin became the first clinically approved drug against an oncogene product as a well-established blocking reagent for tumors with hyperactivity of epidermal growth factor signaling pathways. In the first part of this review we explain basic terms related to the development of antibody-based drugs, give a brief historic perspective of the field, and also touch on topics such as the "humanization of antibodie" or creation of hybrid antibodies. The second part of the review gives an overview of the clinical usage of bispecific antibodies and antibodies "armed"...Continue Reading

Citations

May 31, 2008·Archivum Immunologiae Et Therapiae Experimentalis·Sabine Hombach-KlonischMarek Los
Jul 17, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Sabine Hombach-KlonischMarek Los
Feb 3, 2007·Cancer Immunology, Immunotherapy : CII·Herbert RiechelmannMichael Schmitt
Oct 3, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lee S SchwartzbergArthur C Houts
May 29, 2007·Oncogene·B Bonavida
Feb 21, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Grant SugiuraWalter Mier
Dec 8, 2006·Expert Opinion on Biological Therapy·Steve H Thorne
Sep 18, 2014·Journal of Hematology & Oncology·Alexandra AroninMichal Elhalel
Oct 15, 2009·European Journal of Pharmacology·Marek Los
Nov 15, 2008·Cancer Treatment Reviews·Dorte Lisbet NielsenClaus Kamby
Oct 3, 2006·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Judy E AndersonMarek Los
Jul 18, 2006·Molecular & Cellular Proteomics : MCP·Karl E Krueger, Sudhir Srivastava
Apr 7, 2007·Journal of Immunotherapy·Dallas B Flies, Lieping Chen
Sep 1, 2007·Proteomics. Clinical Applications·Sophie DahanMichel Dominguez
Apr 18, 2017·Biomedit︠s︡inskai︠a︡ khimii︠a︡·M G ZavialovaE N Nikolaev

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.